米替福新治疗PKDL相关角膜炎的临床特征
该回顾性病例系列分析了2018年4月至2019年12月间5例因接受米替福新治疗黑热病后皮肤利什曼病(PKDL)而出现角膜炎的患者。所有患者均表现为周边环状全层角膜基质浸润并形成溃疡性角膜炎,停药并启用糖皮质激素后角膜炎均消退,但双眼受累者预后较差。
要点
- 米替福新相关角膜炎表现为周边环状全层基质浸润并溃疡,类似感染性角膜炎
- 5例均被判定为与米替福新「可能」相关,平均用药48天后发病
- 停药并启用糖皮质激素可使角膜炎消退,单眼者预后优于双眼者
核心结论
- 长期使用米替福新可能引起类似感染性角膜炎的角膜病变,早期诊断、停药并启用糖皮质激素治疗是成功处理的关键。
研究设计与样本
- 回顾性病例系列,纳入2018年4月至2019年12月间5例接受米替福新治疗的PKDL合并角膜炎患者,复习病历并进行药物因果评价。
主要发现
- 眼部症状包括眼痛、眼红、流泪、畏光和视力下降。
- 裂隙灯检查显示所有病例均有周边、近角膜缘、环状、全层角膜基质浸润并导致溃疡性角膜炎。
- 2例为单眼角膜炎,3例为双眼角膜炎。
- 就诊时矫正远视力范围为手动至20/125。
- 所有患者药物因果评价均显示与米替福新为「可能」相关。
关键数值与推荐
- 5例患者在角膜炎发病前接受米替福新平均48天。
- 停药并开始糖皮质激素治疗后所有病例角膜炎均消退。
- 单眼角膜炎经局部糖皮质激素治疗预后改善,双眼角膜炎预后较差。
临床怎么用
- 对使用米替福新的PKDL患者出现角膜炎时,应评估药物相关可能,尽早停药并考虑糖皮质激素治疗,同时注意双眼受累者预后较差。
局限性
- 为回顾性研究,样本量仅5例,未设对照组,结论需更大样本研究验证。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
AIM: To describe the characteristic clinical features and management of keratitis in the patients receiving miltefosine for post-kala-azar dermal leishmaniasis (PKDL). METHODS: The medical records of five patients with PKDL who presented with keratitis were reviewed retrospectively from April 2018 to December 2019. The evaluation included a thorough medical history including details on drugs used, particularly miltefosine. The drug causality assessment was also performed. The clinical and microbiological characteristics of keratitis were noted. RESULTS: The ocular symptoms included pain, redness, watering, photophobia and diminution of vision. Slit-lamp biomicroscopy revealed peripheral, paralimbal, ring-shaped, full-thickness stromal infiltration resulting in ulcerative keratitis in all cases. Two patients had unilateral keratitis, while three had bilateral keratitis. All five patients received miltefosine for an average period of 48 days before the onset of keratitis. The corrected distance visual acuity at presentation ranged from hand movement to 20/125. The causality assessment revealed a 'probable' association between the adverse drug reaction and miltefosine in all patients. Discontinuation of miltefosine and initiation of corticosteroid therapy resulted in resolution of keratitis in all cases. The unilateral keratitis treated with topical corticosteroids had improved outcomes, but poor outcomes were found in the bilateral keratitis. CONCLUSION: These observations indicate that prolonged use of miltefosine might cause keratitis that resembles infectious keratitis. Early diagnosis with discontinuation of the drug and initiation of corticosteroid therapy are the key to successful management.
引用
- Kusumesh R, Ambasta A, Arya LK, et al. Keratitis occurring in patients treated with miltefosine for post-kala-azar dermal leishmaniasis. Br J Ophthalmol. 2020. PMID: 32962993. doi:10.1136/bjophthalmol-2020-317325
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。